Cargando…

MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63

MYCN amplification is a major biomarker of poor prognosis, occurring in 25-30% of neuroblastomas. MYCN plays contradictory roles in promoting cell growth and sensitizing cells to apoptosis. We have recently shown that p53 is a direct transcriptional target of MYCN in neuroblastoma and that p53-media...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gamble, Laura D., Kees, Ursula R., Tweddle, Deborah A., Lunec, John
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2011
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3191119/ https://www.ncbi.nlm.nih.gov/pubmed/21725357 http://dx.doi.org/10.1038/onc.2011.270

Ejemplares similares

Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma
por: Chen, Lindi, et al.
Publicado: (2015)

Structurally diverse MDM2–p53 antagonists act as modulators of MDR-1 function in neuroblastoma
por: Chen, L, et al.
Publicado: (2014)

Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment
por: Yee-Lin, Voon, et al.
Publicado: (2018)

Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer
por: Zanjirband, Maryam, et al.
Publicado: (2016)

Galectin-3 Impairment of MYCN-Dependent Apoptosis-Sensitive Phenotype Is Antagonized by Nutlin-3 in Neuroblastoma Cells
por: Veschi, Veronica, et al.
Publicado: (2012)

Reduced transcriptional activity in the p53 pathway of senescent cells revealed by the MDM2 antagonist nutlin-3
por: Huang, Baoying, et al.
Publicado: (2009)

A p53-independent role for the MDM2 antagonist Nutlin-3 in DNA damage response initiation
por: Valentine, Jane M, et al.
Publicado: (2011)

Downregulation of cyclin D1 sensitizes cancer cells to MDM2 antagonist Nutlin-3
por: Yang, Peipei, et al.
Publicado: (2016)

Molecular mechanisms of MYCN-dependent apoptosis and the MDM2–p53 pathway: an Achille’s heel to be exploited for the therapy of MYCN-amplified neuroblastoma
por: Petroni, Marialaura, et al.
Publicado: (2012)

Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma
por: Chen, Lindi, et al.
Publicado: (2019)

Structure of a Stapled Peptide Antagonist Bound to Nutlin-Resistant Mdm2
por: Chee, Sharon Min Qi, et al.
Publicado: (2014)

p53, SKP2, and DKK3 as MYCN Target Genes and Their Potential Therapeutic Significance
por: Chen, Lindi, et al.
Publicado: (2012)

The Pharmacodynamics of the p53-Mdm2 Targeting Drug Nutlin: The Role of Gene-Switching Noise
por: Puszynski, Krzysztof, et al.
Publicado: (2014)

Inhibition of WIP1 phosphatase sensitizes breast cancer cells to genotoxic stress and to MDM2 antagonist nutlin-3
por: Pechackova, Sona, et al.
Publicado: (2016)

MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma
por: Agarwal, Saurabh, et al.
Publicado: (2018)

TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation
por: Drummond, Catherine J., et al.
Publicado: (2016)

Correction: The Pharmacodynamics of the p53-Mdm2 Targeting Drug Nutlin: The Role of Gene-Switching Noise
Publicado: (2015)

Correction: MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma
por: Agarwal, Saurabh, et al.
Publicado: (2018)

Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer
por: Zanjirband, Maryam, et al.
Publicado: (2017)

MDM2-p53 Interactions in Human Hepatocellular Carcinoma: What Is the Role of Nutlins and New Therapeutic Options?
por: Azer, Samy A.
Publicado: (2018)

Nutlin-3a, an MDM2 antagonist and p53 activator, helps to preserve the replicative potential of cancer cells treated with a genotoxic dose of resveratrol
por: Zajkowicz, Artur, et al.
Publicado: (2013)

MDM2 regulates MYCN mRNA stabilization and translation in human neuroblastoma cells
por: Gu, Lubing, et al.
Publicado: (2011)

MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines
por: Ohnstad, Hege O, et al.
Publicado: (2011)

MDM2 but not MDM4 promotes retinoblastoma cell proliferation through p53-independent regulation of MYCN translation
por: Qi, Dong-Lai, et al.
Publicado: (2016)

Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients
por: Trino, Stefania, et al.
Publicado: (2016)

MDM2 Inhibitor, Nutlin 3a, Induces p53 Dependent Autophagy in Acute Leukemia by AMP Kinase Activation
por: Borthakur, Gautam, et al.
Publicado: (2015)

Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53
por: Walter, Robert F. H., et al.
Publicado: (2018)

MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosis
por: Alborzinia, Hamed, et al.
Publicado: (2022)

MYCN-targeting miRNAs are predominantly downregulated during MYCN-driven neuroblastoma tumor formation
por: Beckers, Anneleen, et al.
Publicado: (2014)

Blocking ETV6/RUNX1-induced MDM2 overexpression by Nutlin-3 reactivates p53 signaling in childhood leukemia
por: Kaindl, U, et al.
Publicado: (2014)

MYCN Function in Neuroblastoma Development
por: Otte, Jörg, et al.
Publicado: (2021)

MYCN and Metabolic Reprogramming in Neuroblastoma
por: Bansal, Mohit, et al.
Publicado: (2022)

Metastasis in neuroblastoma: the MYCN question
por: Bhavsar, Swapnil Parashram
Publicado: (2023)

Nutlin-3, the small-molecule inhibitor of MDM2, promotes senescence and radiosensitises laryngeal carcinoma cells harbouring wild-type p53
por: Arya, A K, et al.
Publicado: (2010)

Therapeutic potential of the MDM2 inhibitor Nutlin-3 in counteracting SARS-CoV-2 infection of the eye through p53 activation
por: Zauli, Giorgio, et al.
Publicado: (2022)

Awakening p53 in senescent cells using nutlin-3
por: Schug, Thaddeus T.
Publicado: (2009)

Nutlin-3 enhances the bortezomib sensitivity of p53-defective cancer cells by inducing paraptosis
por: Lee, Dong Min, et al.
Publicado: (2017)

Nardostachys jatamansi Root Extract Modulates the Growth of IMR-32 and SK-N-MC Neuroblastoma Cell Lines Through MYCN Mediated Regulation of MDM2 and p53
por: Suryavanshi, Snehal, et al.
Publicado: (2017)

Fibroid explants reveal a higher sensitivity against MDM2-inhibitor nutlin-3 than matching myometrium
por: Markowski, Dominique N, et al.
Publicado: (2012)

Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a
por: Fontana, Maria Chiara, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6p27115tlpo03ca4fuir8vscl0